Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
trial enrollment
Biotech
Takeda stops phase 2 post-anesthesia trial over slow enrollment
Stopping the phase 2 danavorexton trial because of slow enrollment marked another twist in the development of the orexin-2 receptor agonist franchise.
Nick Paul Taylor
Oct 31, 2024 5:29am
Kezar suspends key lupus study after 4 deaths
Sep 30, 2024 11:23am
Genfit moves to jump-start enrollment in liver failure trial
Sep 20, 2024 9:47am
Amgen, Merck join academic clinical trial diversity partnership
Sep 16, 2024 3:10pm
Genentech program doubles pace of diverse patient enrollment
Aug 5, 2024 3:15pm
Allucent selected for new BARDA decentralized trial initiative
Jul 10, 2024 5:00am